Skip to main content
Trump Accelerates Psychedelic Drug Review
Lead Story
Politics about 3 hours ago

Trump Accelerates Psychedelic Drug Review

President Donald Trump issued an executive order on April 18, 2026, to fast-track the review and research of psychedelic drugs like ibogaine for serious mental illnesses such as PTSD and severe depression. This landmark directive aims to ease restrictions, prioritize FDA approval, allocate $50 million for ibogaine research, and establish patient access pathways, potentially marking a significant shift in federal drug policy.

President Donald Trump issued an executive order on April 18, 2026, to fast-track the review and research of psychedelic drugs like ibogaine for serious mental illnesses such as PTSD and severe depression.

Catamist Editorial
News Desk

Latest updates

More Articles

Accessibility Options

Font Size

100%

High Contrast

Reading Preferences

Data & Privacy